Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Hallmarks of aging
Research brief

Protocol for a Henan cohort on frailty, sarcopenia, nutrition and physical activity in adults 65+

This abstract describes a planned prospective multicenter observational cohort of 30,000 adults aged 65 and older in Henan, China, starting January 2026, to study how common frailty and sarcopenia are and how they relate to nutritional status and physical activity. No results are reported yet. [1]

Automatic summary · not editorially reviewed

The key findings

  1. The planned cohort aims to enroll 30,000 adults aged 65 and older in Henan from January 2026, with a 3-year study period and follow-up every 6 months. [1]

  2. Frailty is to be assessed with the FRAIL scale and sarcopenia diagnosed per AWGS 2025 criteria; nutrition and physical activity are to be measured with MNA-SF and PASE. [1]

  3. The abstract reports planned methods and aims only, not observed results; the study is registered as NCT07033871. [1]

The source at a glance

Study type / format
Study protocol of a prospective, multicenter, observational cohort study
Population / context
Adults aged 65 years and older in Henan province, China, planned for enrollment from multiple medical institutions.
Summary based on
Study abstract
Publication status
Preprint · peer-review status not confirmed
Original publication
September 25, 2026

Planned Henan cohort of 30,000 adults 65+

The authors describe a prospective, multicenter, observational cohort within the registry study CGACDM – Older Adults in China. They plan to enroll 30,000 participants aged 65 and older from multiple medical institutions in Henan, starting in January 2026, with a 3-year study period and regular follow-up every 6 months. The stated aims are to estimate the prevalence of frailty and sarcopenia, examine their associations with nutritional status and physical activity, and identify predictive factors for region-adapted health strategies.

Supporting source [1]

Planned scales and recorded endpoints

Frailty is to be assessed with the FRAIL scale and sarcopenia diagnosed using the Asian Working Group for Sarcopenia (AWGS) 2025 criteria. Nutritional status is to be measured with the Short-Form Mini Nutritional Assessment (MNA-SF) and physical activity with the Physical Activity Scale for the Elderly (PASE). Routine clinical examinations and long-term endpoints are to be collected, including all-cause death, rehospitalization, falls and cardiovascular events. Data are to be managed on a provincial geriatric quality control platform and analyzed with regression and Cox proportional hazards models.

Supporting source [1]

Protocol only: no results yet reported

This is a study protocol abstract; it reports planned methods and aims, not observed prevalence, associations or outcomes. The authors state that local epidemiological evidence for older people in Henan is insufficient and that current research rarely examines the integrated “frailty–sarcopenia–nutrition–physical activity” axis. Whether the planned associations hold, and whether they are causal, cannot be judged from this abstract. The registration is listed as NCT07033871, registered June 14, 2025, on ClinicalTrials.gov.

Supporting source [1]

How to interpret this

Abstract only; the full text was not reviewed. This is a study protocol, so no prevalence, association or outcome results are reported. Whether the planned associations are causal cannot be determined from this abstract.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    We will enroll 30,000 participants
  2. Finding 2 ↑

    Frailty will be assessed using the FRAIL
  3. Finding 3 ↑

    Clinical trial number: NCT07033871

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…